General description
A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC50 = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC50 = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).
A cell-permeable dioxobenzothiazole compound that acts a selective Cdk4 inhibitor (IC50 = 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A). Exhibit better cytotoxic potential against cancer cells (IC50 = 0.61, 1.08, 0.30, and 1.21 µg/ml against A 549, Col 1, HL-60, and HepG2 tumor cells, respectively) than Cisplatin (Cat. No. 232120).
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Cdk4
Product does not compete with ATP.
Reversible: no
Target IC50: 6.0 µM for Cdk4/D1 and >200 µM for Cdk2/A
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Ryu, C.K., et al. 2000. Bioorg. Med. Chem. Lett.10, 461.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 51284022
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 219478-5MG